The manufacturer focuses on biotechnological research & sterile peptide formulations
When inflammation becomes persistent: Ongoing inflammation can disrupt the skin barrier, slow healing, and increase the likelihood of acne marks and uneven skin tone over time
A key reason for the success of its Zepbound drug is its status as a "dual agonist." Wegovy targets only GLP-1 receptors, whereas tirzepatide (aka Zebound) targets both GLP-1 and GIP receptors, leading to greater overall weight loss
This delayed gastric emptying effect may attenuate somewhat with continued use but remains clinically significant
The effort needed to optimize these regimens can be experienced as aversive, promote frustration, and generate a desire to avoid such effort, aligning with a region of the brain called the anterior midcingulate cortex, as described by Lisa Feldman Barrett and colleagues